Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
Starling Oncology reported Q2 revenue of $161.3 million, up 34.6% year-over-year, driven by a 58% surge in Specialty Pharmacy revenue and the addition of 230,000 capitated lives. The company achieved positive Adjusted EBITDA of $229,000 compared to a loss of $4.1 million in the prior year, prompting management to raise full-year revenue guidance to $650-$670 million.
Key figures
- Revenue
- $161.3 million
- Guidance
- FY2026 Revenue raised to $650-$670 million; Gross Profit raised to $105-$110 million; Adjusted EBITDA updated to $2-$7 million
- Revenue Yoy
- 34.6%
- Gross profit
- $27.2 million
- Cash balance
- 41100000
- Adjusted ebitda
- 229000
- Gross profit margin
- 16.9%
- Capitated lives added
- 230000
- Specialty pharmacy revenue growth
- 58%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.